6McNicholl J M, Bond K B,Ruhadze E R,et al.Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants(Ⅰ): Induction of high titer,long lasting,cross reactive antibodies of broad isotype [J].A2IDS Res H2um Retrovirus2es,1998,14 (16):1 457-1 471.
7Elizabeth J, Lyn M D, Kistonh G M.Immunomodulators and delivery systems for vaccination by mucosal routes [J ].Trends Biotechnol,2001,19(8) :293-304.
9Herbert W J.Mineraloiladjuvantsand the immunization of laboratory animals[M].In:We2irD M. Handbook of Experimental Immunology. 3rd edition. Oxford:Blackwell Scientific Publications,2003:A3.1 A3. 15.
2Li XL,Liu K,Yao HW,et al. Highly pathogenic avian in-fluenza H5N1 in China's Mainland [J]. Int J Environ ResPublic Health,2015,12(5);5026-5045.
3Godinho CA, Yardley L, Marcu A,et al. Increasing the in-tent to receive a pandemic influenza vaccination : testingthe impact of theory-based messages[J]. Prev Med, 2016,89:104-111.
4Rudenko L, Isakova-Sivak I. Pandemic preparedness withlive attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus[J]. Expert Rev Vaccines,2015,14(3):395-412.
5Liang F, Lore K. Local innate immune responses in thevaccine adjuvant-injected muscle[J]. Clin Transl Immunol,2016,5(4):e74.
6Gellin BG, Ampofo WK. Seasonal and pandemic influenzavaccine: demand,supply and vaccine availability [J]. Vac-cine ,2014,32(52):7037-7039.
7Palache A, Oriol -Mathieu V, Abelin A,et al. Seasonalinfluenza vaccine dose distribution in 157 countries(2004-2011)[J]. Vaccine,2014,32(48) :6369-6376.
8Tong S,Zhu X,Li Y,et al. New world bats harbor diverseinfluenza A viruses[J]. PLoS Pathog,2013,9(10) :el003657.
9Hurt AC. The epidemiology and spread of drug resistant hu-man influenza viruses[J]. Curr Opin Virol, 2014,8 ; 22-29.
10Jennings LC. Influenza vaccines:an Asia -Pacific per-spective[J]. Influenza Other Respir Viruses,2013,7 Sup-pl 3:44-51.
